MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas
Author Information
Author(s): Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y, Oosterwijk E
Primary Institution: Nara Medical University
Hypothesis
Could the G250 antigen (MN/CA IX/G250) serve as a potential therapeutic target and tumor marker for renal cell carcinomas?
Conclusion
The MN/CA IX/G250 antigen may be a promising therapeutic target and diagnostic marker for renal cell carcinomas.
Supporting Evidence
- Immunohistochemistry showed strong expression of MN/CA IX/G250 in 87.1% of renal cell carcinoma cases.
- RT-PCR detected MN/CA9/G250 mRNA signals in 93.2% of cases.
- Circulating MN/CA9/G250 expressing cells were found in patients' blood samples.
Takeaway
Researchers looked at a special protein in kidney cancer cells to see if it could help treat or diagnose the disease, and they found it was present in most cases.
Methodology
Immunohistochemical analysis and RT-PCR were used to investigate the expression of MN/CA IX/G250 in renal cell carcinoma samples.
Limitations
High-grade and -stage tumors showed lower expression of the antigen compared to low-grade and -stage tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website